Clinical Trials Directory

Trials / Unknown

UnknownNCT05091645

Translation and Cultural Adaptation of the Groningen Frailty Indicator (GFI) in Patients With Hip Fracture

Translation and Cultural Adaptation of the Greek Version of the Groningen Frailty Indicator (GFI) in Patients With Hip Fracture; a Prospective Cohort Study

Status
Unknown
Phase
Study type
Observational
Enrollment
89 (estimated)
Sponsor
University of Thessaly · Academic / Other
Sex
All
Age
65 Years
Healthy volunteers
Not accepted

Summary

This study attempts to the translation and the cultural adaptation of the Groningen Frailty Indicator (GFI) questionnaire in the Greek population in patients suffering from hip fracture.

Detailed description

Frailty indicates a state of vulnerability in terms of poor health outcomes, such as mortality, hospitalization, institutionalization and loss of function in one or more domains (i.e. physical, psychological, cognitive and social domains). Frailty is not only associated with poor quality of life and life satisfaction but also has an effect on health care demands, as the number of frail people in our aging population will increase. Current literature suggests that frailty is a common condition among elderly patients with hip fracture. Ageing has been associated with a decline in physiological reserves which impedes the body's ability to withstand and recover from minor and major challenges, such as the hip fracture. Hence, accurate diagnosis of frailty seems mandatory. The Groningen Frailty Indicator (GFI) questionnaire is a feasible, reliable and valid self-assessment tool. This study will provide the first official Greek translation and cultural adaptation of the GFI according to the ISPOR (International Society for Pharmacoeconomics and Outcomes Research) guidelines.

Conditions

Interventions

TypeNameDescription
OTHERGFITwo trained raters who will be blinded and will have no access to each other's evaluation, will administer the GFI questionnaire within 24 hours of patients' hospital admission.

Timeline

Start date
2022-02-25
Primary completion
2024-06-30
Completion
2024-07-30
First posted
2021-10-25
Last updated
2023-11-28

Locations

1 site across 1 country: Greece

Source: ClinicalTrials.gov record NCT05091645. Inclusion in this directory is not an endorsement.